The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy
Open accessAbstract
Purpose: Severe skeletal muscle (SM) loss (sarcopenia) is associated with poor cancer outcomes, including reduced survival and increased toxicity. This study investigates SM measures in metastatic breast cancer (MBC) patients receiving first-line taxane-based chemotherapy and evaluates associations with treatment toxicity and other outcomes. Experimental Design: Using computerized tomography (CT) images taken for the evaluation of disease burden, skeletal muscle area (SMA), and density (SMD) were measured at the third lumbar vertebrae. Sarcopenia was defined as skeletal muscle index (SMI = SMA/height2) ≤ 41. Skeletal muscle gauge (SMG) was created by multiplying SMI × SMD. Fisher exact tests, t tests, the Kaplan–Meier method, and Cox regression modeling were used. Results: MBC patients (N = 40), median age 55 (range, 34–80), 58% sarcopenic, median SMG 1296 AU (SD, 522). Grade 3–4 toxicity was found in 57% of sarcopenic versus 18% of non-sarcopenic patients (P = 0.02). Toxicity-related hospitalizations were also higher in sarcopenic patients (39% vs. 0%, P = 0.005) as were any adverse events—defined as any grade 3–4 toxicities, hospitalizations, dose reductions, or dose delay—(74% vs. 35%, P = 0.02). Low SMG was associated with grade 3–4 toxicity (P = 0.04), hospitalization (P = 0.01), and time to treatment failure (for progression or toxicity; P = 0.03). Low SMG had a borderline significant association with any adverse event (P = 0.06) and overall survival (P = 0.07). Conclusions: SM measures are associated with toxicity outcomes and survival in MBC patients receiving first-line taxane-based chemotherapy. Further studies are needed to explore how routinely obtained CT scans can be used to individualize dosing and improve treatment planning. Clin Cancer Res; 23(3); 658–65. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Du BOIS, D. (1916) · Archives of Internal Medicine · doi:10.1001/archinte.1916.00080130010002 · Cited by 4,342
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., Murphy, R., Ghosh, S., Sawyer, M. B., & Baracos, V. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2722 · Cited by 2,680
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Prado, C. M. M., Baracos, V. E., McCargar, L. J., Reiman, T., Mourtzakis, M., Tonkin, K., Mackey, J. R., Koski, S., Pituskin, E., & Sawyer, M. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2242 · Cited by 1,104
Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review
Shachar, S. S., Williams, G. R., Muss, H. B., & Nishijima, T. F. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.030 · Cited by 1,099
Self-citation
Cited by
Caan, B. J., Cespedes Feliciano, E. M., Prado, C. M., Alexeeff, S., Kroenke, C. H., Bradshaw, P., Quesenberry, C. P., Weltzien, E. K., Castillo, A. L., Olobatuyi, T. A., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0137 · Cited by 565
Derstine, B. A., Holcombe, S. A., Ross, B. E., Wang, N. C., Su, G. L., & Wang, S. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-29825-5 · Cited by 507
Approaches to Assessment of Muscle Mass and Myosteatosis on Computed Tomography: A Systematic Review
Amini, B., Boyle, S. P., Boutin, R. D., & Lenchik, L. (2019) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glz034 · Cited by 391
Implications of low muscle mass across the continuum of care: a narrative review
Prado, C. M., Purcell, S. A., Alish, C., Pereira, S. L., Deutz, N. E., Heyland, D. K., Goodpaster, B. H., Tappenden, K. A., & Heymsfield, S. B. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1511918 · Cited by 286
Sarcopenia Is Associated with Quality of Life and Depression in Patients with Advanced Cancer
Nipp, R. D., Fuchs, G., El-Jawahri, A., Mario, J., Troschel, F. M., Greer, J. A., Gallagher, E. R., Jackson, V. A., Kambadakone, A., Hong, T. S., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0255 · Cited by 265
Metadata
- Authors
- Shachar, S. S., Deal, A. M., Weinberg, M., Nyrop, K. A., Williams, G. R., Nishijima, T. F., Benbow, J. M., & Muss, H. B.
- Venue
- Clinical Cancer Research
- Published
- 2017-01-31
- Volume
- 23
- Issue
- 3
- Pages
- 658-665
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2505846117
- Cited by
- 288
- References
- 39
- FWCI
- 14.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0940
- The paper
- Shachar, S. S., Deal, A. M., Weinberg, M., Nyrop, K. A., Williams, G. R., Nishijima, T. F., Benbow, J. M., & Muss, H. B. (2017). Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0940
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.